FANTASTEC Breaks Cover with We Are Colony Acquisition
Fantastec Sports Technology Ltd (Fantastec) Managing Partner Steve Madincea confirmed today the company’s acquisition of We Are Colony Ltd (Colony), an award-winning OTT VOD technology company.
This is the first acquisition by Fantastec, a new sports industry innovator utilising emerging technologies to develop products, platforms and experiences which enable globally distanced fans to better connect and engage more deeply with the sports, teams and athletes they love. Fantastec was founded in 2017 by Madincea, an international sport’s industry entrepreneur.
“We moved quickly with our investment group on Colony because they have the three vital ingredients we look for in any acquisition: industry leading technology, an inspired and capable leadership team, and an ethos of continuous growth and constant innovation which aligns with Fantastec’s ambitions,” Madincea stated.
Colony CEO Sarah Tierney- whose previous roles include Founder of BAFTA-winning television production company Clarity Productions and Head of Content at global ed-tech VOD platform Twig - becomes COO of the Fantastec group.
Tierney commented: “In the face of enormous disruption across the film industry, we built Colony to empower content owners to easily reach engaged audiences around the world. Over the coming years, the sports industry will face similar levels of disruption from a globalising fan base along with rapidly changing tastes, demographics and habits. I am incredibly excited to join the Fantastec family and apply our advanced technology and comprehensive in-market experience to solving a range of challenges and opportunities in the sports sector.”
Madincea stated: “In our quest to use industry leading technologies to better serve the worldwide sport’s fan base we discovered the amazing Colony product and team. It was obvious the OTT VOD technology developed at Colony is an industry leader and has served them well in their prior work in the worldwide movie industry. Fantastec will now utilise these bespoke technologies in several new platforms and products to reach worldwide audiences for all sports. What our first Fantastec acquisition means in practical terms is we can agree terms with any sport, team or athlete and have them up and running on a proven global OTT VOD platform very quickly. We feel this makes for a powerful offering as the rights holder defines the terms not the channel. The purchase of Colony aligns with our Fantastec future fan vision to make engaging with sports more impactful via trailblazing technology”.
NOTES FOR EDITORS:
Fantastec is a unique blend of scientists, engineers, data analysts, designers, researchers, sports marketing creatives and communication professionals inventing the future of international fan engagement.
Utilising new and emerging technologies such as OTT VOD, VR / AR, wearable tech, AI and the Blockchain our mission is to enable globally distanced fans to engage more deeply with the sports, teams and athletes they love.
Steve Madincea is a recognised international sports industry entrepreneur having created, built and led sports sponsorship teams around the world to serve blue chip clients such as Aston Martin, Ford, Coca-Cola, Rolex, Subway, Casio, Samsung, PUMA, Jaguar, AT&T, Bridgestone, Red Bull, Land Rover, Shell, the NFL, the NBA, The UEFA Champions League, Formula 1 and The FIFA World Cup amongst others. Madincea ultimately bundled these disparate worldwide business units together and sold them prior to starting Fantastec.
Global OTT VOD streaming platform Colony was built to empower content owners to reach and engage audiences around the world. Colony's award-winning, end-to-end technology comprises an innovative isomorphic web application framework, video architecture and full back office suite. Colony launched in public beta in Spring 2015, working with film licensors across the world, and attracted registered users in 130 countries.
Colony was founded in 2013 by multi-format content strategy, production and distribution expert, and experienced media entrepreneur, Sarah Tierney. Colony was venture-backed by Archer Gray, Firestartr, The London Co-Investment Fund, Essex Innovation (GV Advisors), Seedcamp and international Angel investors.
Colony’s awards and recognitions include: The 2016 Everline Future 50, the 2016 and 2017 Start-ups 100, The British Small Business Awards, The Drum’s DADI Awards, The Screen Awards, The Drum Online Media Awards, The Digital Entrepreneur Awards and BIMA’s Hot 100 in 2014, 2016 and 2017.
FOR MORE INSIGHTS:
Visit our web-site (www.fantastec.io)
Fantastec Sports Technology Ltd.
Steve Madincea, Managing Partner
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Synteract Announces Collaboration with International Children’s Advisory Network iCAN Research25.6.2018 20:03 | Tiedote
Synteract, an innovative contract research organization (CRO) providing full, phase I-IV services enabling drug development companies to bring new medicines to market, has signed a memo of understanding to partner with the International Children’s Advisory Network (iCAN). A worldwide consortium of children’s advisory groups, iCAN is dedicated to giving children and families a voice in health, medicine, research, and innovation by increasing education about the importance of children’s involvement. Synteract is a sponsor at the 2018 iCAN Research Summit in Edinburgh, Scotland, UK, July 8-13, 2018 and will hold two interactive plenary seminar sessions at the event. With chapters across the U.S. and worldwide, iCAN partners with local children’s hospitals and addresses the needs of pediatric clinical research and healthcare and advocates for patients worldwide. In partnering with iCAN, Synteract will expand its access to children and families familiar with clinical research. iCAN will sup
GA-ASI to Fly First Trans-Atlantic Flight of a MALE RPA25.6.2018 19:55 | Tiedote
On July 10-11, General Atomics Aeronautical Systems, Inc. (GA-ASI) plans to make the first-ever trans-Atlantic flight of a Medium-altitude, Long-endurance (MALE) Remotely Piloted Aircraft (RPA). GA-ASI’s company-owned MQ-9B SkyGuardian RPA is scheduled to fly from the company’s Flight Test and Training Center in Grand Forks, North Dakota, USA, to Royal Air Force (RAF) Fairford in Gloucestershire, UK. The aircraft will then be on static display July 13-15 for the Royal International Air Tattoo (RIAT) airshow being held at RAF Fairford. The flight and display will commemorate the RAF’s centenary celebration (RAF100). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180625005946/en/ GA-ASI’s company-owned MQ-9B SkyGuardian RPA is scheduled to fly from the company’s Flight Test and Training Center in Grand Forks, North Dakota, USA, to Royal Air Force (RAF) Fairford in Gloucestershire, UK. The aircraft will then be on static displa
Quadient Announces General Availability of Quadient Inspire R1225.6.2018 17:30 | Tiedote
www.quadient.com : Quadient, the award-winning leader in Customer Communications Management (CCM), announced the general availability of its newest release, Quadient Inspire R12, which includes the new Digital Advantage Suite. The updated version of Quadient Inspire is designed to give customers and partners greater control over the systems and processes used to drive consistent communications across all channels with an emphasis on digital experiences. With Inspire R12, users design omni-channel communications in days rather than months with a simple, modern and comprehensive platform. The solution makes it possible to change designs and test for all channels in minutes, with fully integrated tracking and approval processes built in. Additionally, R12 integrates all parts of the communications process from linking journey maps to communications, postal sorting, address, phone and email verifications, email delivery, SMS delivery, mail delivery tracking, and production monitoring to re
The Dementia Discovery Fund Raises $350 Million25.6.2018 16:00 | Tiedote
The Dementia Discovery Fund (DDF) today announces the completion of its fundraising, with £250 million ($350 million at the time of completion) raised from an influential group of strategic investors committed to developing new medicines for dementia. The goal was met today with a new investment of $60 million from US AARP, the global nonpartisan organisation dedicated to empowering Americans 50 and older to choose how they live as they age. The fundraising far exceeded its initial target of $200 million (£130 million), making it the first and largest venture fund focused entirely on discovering and developing novel therapies for dementia, including Alzheimer’s disease. The DDF makes early stage venture capital investments to develop novel disease-modifying therapeutics for all forms of dementia. The fund is managed by SV Health and was formed through the collaboration of leading pharmaceutical companies (Biogen, Eli Lilly and Company, GSK, Johnson & Johnson, Otsuka (Astex), Pfizer and
Professor Thierry Philip Takes Office as OECI President25.6.2018 15:22 | Tiedote
Professor Thierry Philip, President of the Institut Curie, has been elected President of the Organisation of European Cancer Institutes ( OECI ) for a three-year term. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180625005600/en/ Pr Thierry Philip (Photo: Business Wire) At the end of June 2018, Professor Philip, an oncologist and pediatrician, will take over as head of this European organization, which brings together 90 institutes and university centers and whose mission is fully devoted to cancer. This European non-governmental, non-profit organization aims to promote cooperation between its members or associate members and pursues a triple objective: to provide cancer patients in Europe with equal access to high-quality care; to assist European institutes with the implementation of a quality system for oncology care; to promote and accelerate the progress of translational research. In this regard, half of the 90 OECI ce
Boehringer Ingelheim and Lilly announce positive top-line Phase III data results for empagliflozin as adjunct to insulin in type 1 diabetes25.6.2018 15:07 | Tiedote
Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced that both randomised controlled trials in the EASE phase III programme, investigating the use of empagliflozin in combination with insulin therapy in adults with type 1 diabetes, met their primary endpoint. The primary efficacy endpoint, defined in both trials as placebo-corrected change from baseline in HbA1c after 26 weeks of treatment, was met for all investigated doses of empagliflozin (2.5, 10, and 25 mg). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180625005579/en/ Type 1 diabetes currently affects approximately 30 million adults worldwide.1 It is an autoimmune disease in which the body does not produce sufficient amounts of insulin and therefore requires life-long daily insulin administration to regulate blood sugar. For some people with type 1 diabetes, it may be challenging to manage blood sugar levels with insulin alone. People with type
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme